User:Mr. Ibrahem/Burosumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | FGF 23 |
| Clinical data | |
| Pronunciation | bur OH sue mab |
| Trade names | Crysvita |
| Other names | KRN-23, KRN23, burosumab-twza |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a618034 |
| License data | |
| Pregnancy category |
|
| Routes of administration | Subcutaneous |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Elimination half-life | 16.4 days[7] |
| Chemical and physical data | |
| Formula | C6388H9904N1700O2006S46 |
| Molar mass | 144090.15 g·mol−1 |
Burosumab, sold under the brand name Crysvita, is a medication used to treat X-linked hypophosphatemia and tumor-induced osteomalacia.[5] It may be used in those over 5 months old.[5] It is given by injection under the skin.[8]
Common side effects include fever, pain at the site of injection, cough, headache, restless leg syndrome, cavities, and tooth abscess.[5] Other side effects may include allergic reactions, high phosphate, and nephrocalcinosis.[5] Safety in pregnancy is unclear.[5] It is a monoclonal antibody that binds to and blocks the protein FGF23, allowing the kidneys to reabsorb phosphate.[9]
Burosumab was approved for medical use in the United States and Europe in 2018.[5][9] In the United States 30 mg costs about 12,200 USD as of 2022.[10]
References[edit]
- ^ a b "Crysvita". Therapeutic Goods Administration (TGA). 17 September 2021. Archived from the original on 17 September 2021. Retrieved 17 September 2021.
- ^ "Crysvita burosumab 10 mg/mL solution for injection in a 5 mL vial". Therapeutic Goods Administration (TGA). Archived from the original on 17 September 2021. Retrieved 17 September 2021.
- ^ "Crysvita burosumab 10 mg/mL solution for injection in a 5 mL vial" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 17 September 2021. Retrieved 17 September 2021.
- ^ "Crysvita 10 mg solution for injection - Summary of Product Characteristics (SmPC)". (emc). 20 April 2020. Archived from the original on 21 June 2020. Retrieved 19 June 2020.
- ^ a b c d e f g h i "Crysvita- burosumab injection". DailyMed. Archived from the original on 17 September 2021. Retrieved 17 September 2021.
- ^ "Drug Approval Package: Crysvita (burosumab-twza)". U.S. Food and Drug Administration (FDA). 15 May 2018. Archived from the original on 28 February 2020. Retrieved 28 February 2020.
- ^ Zhang X, Imel EA, Ruppe MD, Weber TJ, Klausner MA, Ito T, et al. (February 2016). "Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia". Journal of Clinical Pharmacology. 56 (2): 176–85. doi:10.1002/jcph.570. PMC 5042055. PMID 26073451.
- ^ "Burosumab". SPS - Specialist Pharmacy Service. 30 November 2016. Archived from the original on 22 June 2020. Retrieved 12 January 2022.
- ^ a b "Crysvita EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 July 2021. Retrieved 1 March 2020.
This article incorporates text from this source, which is in the public domain.
- ^ "Crysvita Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 April 2021. Retrieved 12 January 2022.
